PFM
SIOX

Privium Fund Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Privium Fund Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,806,542
Closed -$2.37M – 306
2021
Q4 		$2.37M Buy
+1,806,542
New +$3.21M 0.47% 33

Other funds holding SIOX

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Privium Fund Management's SIOX Position: Q1 2022 in Review

Privium Fund Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 1,806,542 shares — an estimated $2.37M sold.

Privium Fund Management first reported a position in SIOX in Q4 2021 and held it in 1 quarter. The position peaked at $2.37M in Q4 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • Privium Fund Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Privium Fund Management sold 1,806,542 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $2.37M.
  • Privium Fund Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Privium Fund Management's Sio Gene Therapies Inc. Common Stock position peaked at $2.37M in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Privium Fund Management's 13F filing for Q1 2022, filed 10 May 2022.